Comprehensive Pharmacology Notes for Acute Symptomatic Bradycardia and Chronic Orthostatic Hypotension

ACUTE SYMPTOMATIC BRADYCARDIA

First-Line Pharmacologic Agent: Atropine

Atropine is the primary drug for acute symptomatic bradycardia, administered at 0.5-1 mg IV, repeated every 3-5 minutes to a maximum total dose of 3 mg 1, 2, 3. This anticholinergic agent blocks muscarinic acetylcholine receptors, facilitating sinoatrial conduction and increasing sinus node automaticity with a half-life of approximately 2 hours 2.

Specific Indications for Atropine:

Symptomatic sinus bradycardia (heart rate <50 bpm with hypotension, ischemia, or ventricular escape rhythms) 1
Ventricular asystole 1
Symptomatic AV block at the AV nodal level (second-degree type I or third-degree with narrow-complex escape rhythm) 1
Bradycardia with hypotension after nitroglycerin administration 1
Acute inferior MI with type I second-degree AV block plus hypotension, ischemic discomfort, or ventricular arrhythmias 1

Critical Dosing Considerations:

Never administer doses <0.5 mg - paradoxical bradycardia may occur due to parasympathomimetic response 1
Titrate to achieve minimally effective heart rate (approximately 60 bpm), not maximal heart rate 1
Most effective within 6 hours of acute MI symptom onset 1
Peak action occurs within 3 minutes of IV administration 1

Contraindications and Cautions:

Class III (Harm): Post-heart transplant patients without autonomic reinnervation - atropine is ineffective and should NOT be used 2, 3
Avoid in: Infranodal AV block (wide-complex escape rhythm, typically with anterior MI) 1
Use cautiously in acute MI due to protective parasympathetic tone against VF and infarct extension 1
May worsen type II second-degree AV block by increasing sinus rate while enhancing the block 1

Second-Line Agents: Beta-Agonists and Vasopressors

When atropine fails or is contraindicated, beta-agonists may be considered in patients at low likelihood of coronary ischemia 2, 3.

Epinephrine

Dosing: 2-10 mcg/min IV or 0.1-0.5 mcg/kg/min, titrated to effect 4, 2, 4, 3
For 70-kg adult: Start 7-35 mcg/min 4
Strong alpha and beta-adrenergic effects: increases chronotropy, inotropy, blood pressure, and myocardial oxygen consumption 2
Useful for symptomatic bradycardia when atropine and transcutaneous pacing fail 4

Dopamine

Dosing: 5-20 mcg/kg/min IV, starting at 5 mcg/kg/min, increasing by 5 mcg/kg/min every 2 minutes 2, 3
Particularly useful for hypotension associated with symptomatic bradycardia 4
Warning: Doses >20 mcg/kg/min may cause vasoconstriction or arrhythmias 2, 3
Mixed effects: vasodilatory at 1-2 mcg/kg/min, chronotropic/inotropic at 5-20 mcg/kg/min, vasoconstrictive at higher doses 2

Isoproterenol

Dosing: 20-60 mcg IV bolus followed by 10-20 mcg doses, or infusion of 1-20 mcg/min based on heart rate response 2, 3
Nonselective beta-agonist with chronotropic and inotropic effects without vasopressor effect 2
Monitor closely: May cause ischemic chest pain; some patients require higher doses or may not respond robustly 2

Dobutamine

Dosing: 5-10 mcg/kg/min 4
Potent beta-adrenergic agonist with vasodilating effects that may reduce systemic vascular resistance 4

Special Situations and Antidotes

Beta-Blocker or Calcium Channel Blocker Overdose

Glucagon 2, 3:

3-10 mg IV bolus with infusion of 3-5 mg/h
Class IIa recommendation for symptomatic bradycardia from beta-blocker or CCB overdose

High-Dose Insulin Therapy 2, 3:

IV bolus of 1 unit/kg followed by infusion of 0.5 units/kg/h
Class IIa recommendation
Critical: Follow glucose and potassium levels closely

Calcium (for CCB overdose) 2, 3:

10% calcium chloride: 1-2 g IV every 10-20 min or infusion of 0.2-0.4 mL/kg/h
10% calcium gluconate: 3-6 g IV every 10-20 min or infusion of 0.6-1.2 mL/kg/h
Class IIa recommendation

Digoxin Overdose

Digoxin antibody fragment 2, 3:

Dosage dependent on amount ingested or known digoxin concentration
One vial binds approximately 0.5 mg of digoxin
Administer over at least 30 minutes; may be repeated

Post-Heart Transplant Bradycardia

Aminophylline or Theophylline 2, 3:

Aminophylline: 6 mg/kg in 100-200 mL IV fluid over 20-30 min
Theophylline: 300 mg IV, followed by oral 5-10 mg/kg/day titrated to effect
Class IIa recommendation for post-transplant patients
Therapeutic serum levels: 10-20 mcg/mL (usual post-transplant dosages average 450±100 mg/day)

Spinal Cord Injury

Aminophylline or Theophylline 2, 3:

Same dosing as post-transplant
Effective dosages often result in serum levels below usual therapeutic range of 10-20 mcg/mL

Transcutaneous and Transvenous Pacing

Transcutaneous pacing is emphasized in modern guidelines as suitable for standby pacing in acute MI, especially for moderate-risk patients not requiring immediate pacing 1. It avoids complications of intravenous systems and is well-suited for patients receiving thrombolytic therapy 1.

Class II Indications for Temporary Pacing:

Sinus bradycardia (rate <50 bpm) with hypotension (SBP <80 mmHg) unresponsive to drug therapy 1
Symptomatic bradycardia unresponsive to atropine 1
Bilateral BBB (alternating BBB or RBBB with alternating LAFB/LPFB) 1
New or indeterminate bifascicular block with first-degree AV block 1
Mobitz type II second-degree AV block 1

CHRONIC ORTHOSTATIC HYPOTENSION

Non-Pharmacological Management (First-Line)

Non-pharmacological strategies are the foundation of orthostatic hypotension treatment 5, 6, 7. The therapeutic goal is symptom relief and fall prevention, not blood pressure normalization 6.

Essential Non-Pharmacological Interventions:

Medication review: Discontinue or adjust blood pressure-lowering drugs, psychotropic drugs, diuretics, alpha-adrenoreceptor antagonists 5
Behavioral modifications:
- Gradual staged movements with postural change 5
- Physical counter-maneuvers: leg-crossing, stooping, squatting, tensing muscles 5
- Head-up bed position during sleep (elevate head of bed 10-20 degrees) 5
- Avoid large carbohydrate-rich meals 5
- Limit alcohol 5
Volume expansion:
- Increased fluid intake (2-2.5 L/day) 5
- Increased salt intake (6-10 g/day if not contraindicated) 5
- Rapid water drinking (500 mL rapidly) 5
Compression garments: Elastic garments over legs and abdomen 5
Portable folding chairs for use when symptoms occur 5

Pharmacological Management

First-Line Pharmacological Agents

Midodrine 5, 8, 9, 6, 10:

The only FDA-approved medication specifically for symptomatic orthostatic hypotension 5
Dosing: Individually tailored, up to 2-4 times 10 mg/day 5
Administration: First dose taken before arising; avoid several hours before planned recumbency, particularly in patients with supine hypertension 5
Mechanism: Peripheral selective α1-adrenergic agonist causing arteriolar constriction and venoconstriction 5
Adverse effects: Pilomotor reactions, pruritus, supine hypertension, bradycardia, GI symptoms, urinary retention 5
Evidence: Consistently improves orthostatic symptoms; recommended as first-line therapy 8, 6, 10

Droxidopa 8, 9, 11, 6, 10:

FDA-approved in 2014 for neurogenic orthostatic hypotension 11
Synthetic oral norepinephrine prodrug 11
Evidence: Consistently improves orthostatic symptoms; recommended as first-line therapy 8, 6, 10
Advantage: May be less likely than midodrine to exacerbate supine hypertension based on limited meta-analysis 9
Well-tolerated, effective, and easy to use 11

Second-Line Pharmacological Agents

Fludrocortisone (9-α-fluorohydrocortisone) 5, 8, 6, 10:

Dosing: Initial 0.05-0.1 mg daily, titrate to 0.1-0.3 mg daily 5
Mechanism: Sodium retention, direct vasoconstriction on partially denervated vessels, increased water content of vessel wall 5
Adverse effects: Supine hypertension, hypokalemia, congestive heart failure, peripheral edema 5
Evidence: Moderate efficacy; use when first-line agents fail 8, 6, 10

Pyridostigmine 8, 6, 10:

Evidence: Moderate efficacy, particularly in combination therapies 10
Provides additional benefits when combined with other agents 10

Atomoxetine 8, 6, 12:

Emerging evidence: Low-dose atomoxetine shows promise, especially in central autonomic failure 8
May be viable alternative treatment option 8
Norepinephrine transporter inhibition represents emerging strategy 12

Third-Line and Adjunctive Agents

Erythropoietin 5:

Indication: Diabetic patients with hemoglobin <11 g/dL 5
Dosing: 25-75 U/kg three times/week subcutaneously or IV, target hemoglobin 12 g/dL, then lower maintenance doses 5
Mechanism: Increases red cell mass and central blood volume, corrects anemia, neurohumoral effects on vascular wall 5

Desmopressin acetate 5:

Vasopressin analogue useful for nocturnal polyuria and morning orthostatic hypotension 5

Somatostatin analogues (Octreotide) 5, 8, 10:

Inhibits release of vasoactive GI peptides, enhances cardiac output, increases forearm and splanchnic vascular resistance 5
Warning: Severe hypertension possible in diabetic patients 5
Demonstrated potential for refractory OH but lacks robust evidence 10

Caffeine 5:

Useful in attenuating postprandial hypotension in autonomic failure 5

Acarbose 5:

Useful in attenuating postprandial hypotension in autonomic failure 5

Special Populations and Considerations

Diabetic Patients with Cardiovascular Autonomic Neuropathy

Pharmacologic modulation of autonomic tone 5:

Cardioselective β-blockers without intrinsic sympathomimetic activity (metoprolol, nebivolol, bisoprolol) may increase HRV 5
Can treat resting tachycardia associated with CAN 5
ACE inhibitors, ARBs, digoxin, verapamil may increase HRV 5

Pathogenetically oriented therapy 5:

α-lipoic acid (antioxidant) showed favorable effects on HRV in Phase II RCTs 5
Vitamin E and C-peptide also showed benefits 5

Hypertrophic Cardiomyopathy with Acute Hypotension

Intravenous phenylephrine (or another pure vasoconstricting agent) is recommended for acute hypotension in obstructive HCM patients who do not respond to fluid administration 13.

Class III (Harm): Dopamine, dobutamine, norepinephrine, and other IV positive inotropic drugs are potentially harmful for acute hypotension in obstructive HCM 13.

Postural Orthostatic Tachycardia Syndrome (POTS)

Ivabradine 14:

Dosing: 2.5-7.5 mg twice daily 14
Weak recommendation for POTS treatment 14
Alternative to nonselective β-blocker therapy, particularly with prominent symptomatic orthostatic tachycardia 14
Warning: May be teratogenic; adequate contraception required in women of childbearing potential 14
Availability may be limited in Canada due to off-label use 14

Central sympatholytic agents 14:

Clonidine: 0.1-0.2 mg up to 3 times daily 14
Methyldopa: Starting 125 mg once at bedtime, titrate to 250 mg twice daily 14
Used for prominent hyperadrenergic symptoms (palpitations, tremors, significant orthostatic hypotension) 14
May not be tolerated with supine hypotension or orthostatic hypotension 14
Side effects: sedation, dry mouth 14

Chronic Symptomatic Bradycardia (Non-Acute)

Theophylline 15, 16:

Dosing: 400-600 mg/day (approximately 8 mg/kg/day) in divided doses 16
Target steady-state serum concentration: 5-15 mg/L 16
Mechanism-based therapy: Most effective for bradycardic phenotype of extrinsic cause 15
Lower initial dosages appropriate in elderly due to decreased clearance 16
Contraindications: Bradycardia-tachycardia syndrome, frequent ventricular ectopy 16
Monitoring: Adjust based on heart rate, clinical symptoms, and occasional theophylline concentrations 16
Consider drug interactions (ciprofloxacin), altered metabolism (smoking), comorbidities (hepatic disease, heart failure) 16

Treatment Algorithm for Orthostatic Hypotension

Step 1: Implement all non-pharmacological measures (medication review, behavioral modifications, volume expansion, compression garments)

Step 2: If symptoms persist, initiate midodrine or droxidopa as first-line pharmacotherapy

Step 3: If inadequate response or intolerance to first-line agents, add or switch to fludrocortisone or pyridostigmine

Step 4: Consider atomoxetine for central autonomic failure or as alternative

Step 5: For refractory cases, consider adjunctive agents (erythropoietin if anemic, desmopressin for nocturnal polyuria, octreotide, caffeine, acarbose)

Throughout: Balance symptom relief against supine hypertension risk; individualize based on cardiovascular comorbidities 9, 6

Critical Warnings and Pitfalls

Supine hypertension: Major concern with all pressor agents; monitor closely and adjust timing of doses 5, 9, 6
Postprandial hypotension: Screen all OH patients; may require specific interventions (caffeine, acarbose, smaller meals) 5, 6
Drug-drug interactions: Many cardiovascular medications (vasodilators, β-blockers) exacerbate OH 9
Treatment targets: Focus on symptom relief and fall prevention, NOT blood pressure normalization 6
Mechanism-based selection: Hypotensive phenotype requires blood pressure-elevating agents; bradycardic phenotype requires chronotropic agents 15
Avoid in acute MI: Atropine should be used cautiously due to protective parasympathetic tone 1
Post-transplant: Atropine is ineffective and contraindicated; use aminophylline/theophylline instead 2, 3

Can you provide comprehensive pharmacology notes for treating acute symptomatic bradycardia and chronic orthostatic hypotension in adults?

Have a follow-up question?